Short answer
Pacira BioSciences, Inc. (PCRX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $177M (down 1.6% year over year) with net income of $29M.
Q3 2026 key financials · XBRL
- Revenue
- $177M
- −1.6% YoY · −8.2% QoQ
- Net income
- $29M
- +425.1% YoY · +513.0% QoQ
- Operating margin
- 12.6%
- EPS (diluted)
- $0.70
- +483.3% YoY · +483.3% QoQ
Source: XBRL data from the Pacira BioSciences, Inc. (PCRX) Q3 2026 10-Q on SEC EDGAR. USD.
Pacira BioSciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $176.7M, down 2% YoY from $179.5M
- Gross margin decreased two percentage points YoY, driven by higher ZILRETTA costs and inventory reserves
- EXPAREL revenue $142.5M, up 2%; ZILRETTA revenue $29.8M, up 3%
- Operating cash flow $133.2M through September, with $73.6M divestiture proceeds and $50.0M share repurchases
- Outlook: cash resources sufficient for 12 months; tariff volatility expected to pressure gross margins
Risk Factors
- New acquisition risk: Viatris merger announced October 8, 2026, creating employee, customer, supplier and stock-price disruption
- Most material update: Merger agreement restricts acquisitions, debt, equity issuance and capital expenditures without Viatris consent
- Regulatory and legal risk: Hart-Scott-Rodino clearance and absence of governmental legal restraints required to complete the merger
- Financial risk: $7.4 million merger costs incurred by September 30, 2026, with additional fees payable regardless of closing
- Divestiture risk: Up to $70.0 million of iovera° milestone payments depend on Zimmer revenue targets through December 31, 2031
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pacira BioSciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.